

HALOZYME THERAPEUTICS INC

Form 8-A12B

May 09, 2007

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**FORM 8-A**  
**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES**  
**PURSUANT TO SECTION 12(b) OR (g) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**  
**HALOZYME THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

**Nevada**  
(State of incorporation)

**88-0488686**  
(I.R.S. Employer Identification No.)

**11588 Sorrento Valley Road, Suite 17**  
**San Diego, California**  
(Address of principal executive offices)

**92121**  
(Zip Code)

**Securities to be registered pursuant to Section 12(b) of the Act:**

Title of each class  
to be so registered

Name of each exchange on which  
each class is to be registered

Common Stock, \$0.001 Par Value

The Nasdaq Stock Market LLC

If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.

If this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.

**Securities Act registration statement file number to which this form relates:**

Not applicable

**Securities to be registered pursuant to Section 12(g) of the Act:**

None

Item 1. Description of Registrant's Securities to be Registered

The capital stock of Halozyme Therapeutics, Inc. (the **Company**) to be registered on The Nasdaq Stock Market LLC is the Company's Common Stock with a par value of \$0.001 per share.

The description of the Company's Common Stock contained in the Company's prospectus dated December 14, 2005, as a part of the Registration Statement on Form S-3, File No. 333-125731, is incorporated by reference, subject to the rights described in the following sentence and provided that 150,000,000 shares of Common Stock are now authorized and 71,913,411 shares of Common Stock were outstanding as of April 30, 2007. In addition, the description of the rights held by each share of Company Common Stock pursuant to the Company's Stockholder Rights Plan, as set forth in the Company's Form 8-K filed on May 8, 2006, is also incorporated by reference.

Item 2. Exhibits

Not applicable.

---

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Date: May 9, 2007

Halozyme Therapeutics, Inc.

By: /s/ David Ramsay  
David Ramsay  
Secretary and Chief Financial Officer